U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H24NO2S.I
Molecular Weight 445.358
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIEMONIUM IODIDE

SMILES

[I-].C[N+]3(CCC(O)(C1=CC=CS1)C2=CC=CC=C2)CCOCC3

InChI

InChIKey=IOFXEUZPIIUQAG-UHFFFAOYSA-M
InChI=1S/C18H24NO2S.HI/c1-19(11-13-21-14-12-19)10-9-18(20,17-8-5-15-22-17)16-6-3-2-4-7-16;/h2-8,15,20H,9-14H2,1H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula HI
Molecular Weight 127.9124
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C18H23NO2S
Molecular Weight 317.446
Charge 0
Count
Stereochemistry MIXED
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Tiemonium (often used in a form of iodide or methylsulphate salt) is a muscarinic acetylcholine receptor antagonist, which is available in Asia (mainly Bangladesh) for the alleviation of muscle spasms of the intestine, biliary system, uterus and urinary bladder in gastrointestinal, biliary, urinary and gynecological diseases.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
Palliative
NORVIS

Approved Use

Norvis is an antispasmodic drug. It reduces muscle spasms of the intestine, biliary system, uterus and urinary bladder. It is indicated for the pain in gastrointestinal and biliary disease in the urology and gynecology such as gastroenteritis, diarrhea, dysentery, biliary colic, enterocolitis, cholecystytis, colonopathyes, mild cystitis, and spasmodic dysmenorrhoea.
PubMed

PubMed

TitleDatePubMed
Orofacial dyskinesia associated with tiemonium.
2007 Dec
Direct asymmetric catalytic thienylaluminum addition to ketones: a concise approach to the synthesis of (S)-tiemonium iodide.
2009 Aug 6
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
6,7-Difluoro-1,4-dihydro-1-methyl-4-oxo-3-quinolinecarboxylic acid, a newly designed fluorescence enhancement-type derivatizing reagent for amino compounds.
2010 Mar
Patents

Sample Use Guides

Recommended oral dose of tiemonium (in form of methylsulphate salt) tablet is 2-6 tablets (100-300 mg) daily in divided dosage as required. Tiemonium can be also given as an injection (5 or 10 mg) three times daily, through Intravenous route or Intramuscular route. Suppository: recommended dose is 1 suppository (each suppository contains 20 mg methylsulphate salt) two or three times daily, through rectal route.
Route of Administration: Other
Human colon cancer cell lines, LOVO, were incubated in 2 ml of fresh complete medium containing 10(-2) M tiemonium methylsulfate for five days. Under the tested concentration tiemonium methylsulfate lead to a decrease of cell proliferation.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:49:41 GMT 2023
Edited
by admin
on Fri Dec 15 15:49:41 GMT 2023
Record UNII
FZ2LZ7U304
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIEMONIUM IODIDE
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
TIEMONIUM IODIDE [JAN]
Common Name English
Tiemonium iodide [WHO-DD]
Common Name English
TE 114
Code English
4-(3-HYDROXY-3-PHENYL-3-(2-THIENYL)PROPYL)-4-METHYL-MORPHOLINIUM IODIDE
Systematic Name English
tiemonium iodide [INN]
Common Name English
TIEMONIUM IODIDE [MART.]
Common Name English
TE-114
Code English
TIEMONIUM IODIDE [MI]
Common Name English
VISCERALGINE
Brand Name English
Classification Tree Code System Code
WHO-ATC A03DA07
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
WHO-VATC QA03DA07
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
WHO-VATC QA03AB17
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
WHO-ATC A03AB17
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
NCI_THESAURUS C29704
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
Code System Code Type Description
EVMPD
SUB11031MIG
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
FDA UNII
FZ2LZ7U304
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
DRUG BANK
DB13666
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID00875078
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
ChEMBL
CHEMBL2110651
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
WIKIPEDIA
Tiemonium iodide
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
NCI_THESAURUS
C75286
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
PUBCHEM
72142
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
SMS_ID
100000082188
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
CAS
144-12-7
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
ECHA (EC/EINECS)
205-616-5
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
INN
1543
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
MESH
C003602
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY
MERCK INDEX
m10857
Created by admin on Fri Dec 15 15:49:41 GMT 2023 , Edited by admin on Fri Dec 15 15:49:41 GMT 2023
PRIMARY Merck Index
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY